Use the form on the right to contact us.
You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.
123 Street Avenue, City Town, 99999
(123) 555-6789
email@address.com
You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.
Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.
type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的，洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de
Filtering by Category: Type I News
There is now a webpage where customers, healthcare providers and loved ones can check the status of all Dexcom systems 24 hours a day, 7 days a week. This page is the first of several updates that Dexcom is putting in place. Spoilers: Look for the launch of an in-app messaging feature that is planned for the near future.
Arden woke up for school at 6:30 am with a BG of 71 but wasn’t planning on eating before she left for school. About 45 minutes later her BG began to drift lower and she still wasn’t hungry. The drift had momentum because her basal rate increases at 7 am for her school day insulin needs. So we bumped the number with chewable vitamins - just 5 carbs but they worked perfectly. Her BG went to 101 and then drifted back to 91. She did not eat until noon and never experienced a low.
PLAINSBORO, N.J., Jan. 6, 2020 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp® (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.1 Fiasp® is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Fiasp® is now available for use in children and adults in three different dosing options: multiple daily injections (MDI), continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
Diabetes is one of the most common chronic conditions diagnosed in childhood, with nearly 18,000 new cases of type 1 diabetes each year.2,3 Managing diabetes can be challenging for parents and caregivers given it is hard to know exactly how much or how quickly their children will eat, making mealtime insulin dosing difficult.3,4,5 Conventional rapid-acting insulins must be administered ahead of meals, which requires some guesswork to dose properly, and children living with diabetes may not achieve adequate blood sugar control.3,4,5,6
“As a parent of a son living with type 1 diabetes, I know first-hand how tough it can be to address the inevitable blood sugar spikes around mealtimes,” said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk. “Children can be unpredictable and having the option of a fast-acting insulin that doesn’t require pre-meal dosing like Fiasp® is a welcome development for the diabetes community.”
The approval is based on the FDA's review of data from the onset 7 clinical trial, which confirmed the efficacy and safety of Fiasp® in children. 7
For information on cost and savings offers, including co-pay and patient assistance programs, visit myfiaspcost.com.
“To be out of cardiovascular and diabetes is not easy for a company like ours with an incredibly proud history. As tough a choice as that is, we’re making that choice.”
The maker of the world’s top-selling insulin has given up on finding new diabetes drugs. which makes Lantus, said Monday it would stop investing in diabetes research after years of frustrated attempts to bring a fresh blockbuster to the market.
The decision is part of a broader strategic overhaul by new Chief Executive Paul Hudson, who hopes to reinvigorate growth at the French health-care giant by focusing on fewer, more specialized disease areas such as cancer—mirroring a move being made across the drug industry.
Read the entire article here
press release
PLAINSBORO, N.J., Oct. 22, 2019 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL to include use in insulin infusion pumps for the improvement of glycemic control in adults with type 1 or type 2 diabetes.1 Fiasp®, a rapid-acting insulin, was approved by the FDA in 2017 for use by intravenous infusion under supervision by a healthcare professional or by subcutaneous multiple daily injection (MDI) in adults with diabetes.
There are estimated to be more than 350,000 insulin infusion pump users in the U.S.2,3,4 An insulin pump is a small, programmable, battery-operated device that delivers insulin under the skin. Fiasp® should be used in accordance with the insulin pump's instructions for use. Fiasp® is available in multiple dosing options for multiple daily injections (MDI) as well as continuous subcutaneous insulin infusion1:
10 mL vial for use in insulin pumps or MDI
3 mL FlexTouch® for MDI
3 mL PenFill® Cartridge for NovoPen Echo for MDI
"People living with diabetes are looking for treatment options that fit into their lifestyles and shifting schedules, and for many, an insulin pump is an important part of their regimen," said Todd Hobbs, vice president and U.S. chief medical officer of Novo Nordisk. "Since the launch of Fiasp®, we've heard time and again from the diabetes community about the need to make it available for adult insulin pump users. This label update will now enable adult patients to use Fiasp® in their pumps, which is an important part of our ongoing commitment to patient choice and meeting the needs of people living with type 1 and type 2 diabetes."
The label change is based on the FDA's review of data from the onset 5 clinical trial, which confirmed the efficacy and safety of Fiasp® when used in insulin infusion pumps in adults with diabetes. 5 Fiasp® has been shown to be well-tolerated and effective in pumps releasing steady doses throughout the day and mealtime doses during meals. The pump should be programmed based on guidance from healthcare providers and the pump maker's instructions.
